A phase 2 clinical study presented at the 2022 clinical trials on Alzheimer’s disease (CTAD) conference showed that NE3107 was associated with improvement in CSF p-tau in patients with MCI or mild dementia [254]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.